Cargando…

Toward precision medicine in inflammatory breast cancer

Inflammatory breast cancer (IBC) is an aggressive, although infrequent form of invasive breast cancer. Despite some advances in systemic treatment, even in the early setting, with combined-modality approach being the current recommended standard of care, the prognosis of IBC still remains unfavorabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viale, Giulia, Marra, Antonio, Curigliano, Giuseppe, Criscitiello, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798747/ https://www.ncbi.nlm.nih.gov/pubmed/35117125 http://dx.doi.org/10.21037/tcr.2019.05.04

Ejemplares similares

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Expression of tumor-associated antigens in breast cancer subtypes
por: Curigliano, Giuseppe, et al.
Publicado: (2019)

Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016)

Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer
por: Esposito, Angela, et al.
Publicado: (2015)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Toward precision medicine of breast cancer
por: Carels, Nicolas, et al.
Publicado: (2016)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Immune approaches to the treatment of breast cancer, around the corner?
por: Criscitiello, Carmen, et al.
Publicado: (2014)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
por: Ivanova, Mariia, et al.
Publicado: (2023)

Best management of locally advanced inoperable breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
por: Fusco, Nicola, et al.
Publicado: (2020)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
por: Gelao, Lucia, et al.
Publicado: (2014)

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
por: Trapani, Dario, et al.
Publicado: (2020)

The PROMISe to increase precision in adjuvant therapy for early breast cancer: To “Type” or to “Print”?
por: Cardoso, Fatima, et al.
Publicado: (2018)

Tumour dormancy and clinical implications in breast cancer
por: Gelao, L, et al.
Publicado: (2013)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives
por: Criscitiello, Carmen, et al.
Publicado: (2014)

From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26–30th September 2014
por: Curigliano, Giuseppe
Publicado: (2014)

Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine
por: Panagopoulou, Maria, et al.
Publicado: (2021)

Precision medicine in breast cancer: reality or utopia?
por: Bettaieb, Ali, et al.
Publicado: (2017)

Towards Precision Medicine for Osteoarthritis: Focus on the Synovial Fluid Proteome
por: Moretti, Lorenzo, et al.
Publicado: (2022)

Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine
por: Dupain, Célia, et al.
Publicado: (2017)

Precision Medicine in Inflammatory Bowel Disease
por: Annese, Vito, et al.
Publicado: (2023)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
por: Licata, Luca, et al.
Publicado: (2023)

Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
por: Tarantino, Paolo, et al.
Publicado: (2019)

Master protocols in immuno-oncology: do novel drugs deserve novel designs?
por: Mazzarella, Luca, et al.
Publicado: (2020)

Towards Precision Medicine in Systemic Lupus Erythematosus
por: Lever, Elliott, et al.
Publicado: (2020)

Towards precision medicine in thyroid cancer
por: Xiao, Haipeng, et al.
Publicado: (2020)

Are all cyclin-dependent kinases 4/6 inhibitors created equal?
por: Marra, Antonio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lpnfnngiaa721gdahhambl05p6